Literature DB >> 7766535

Problem solving in schizophrenia: a specific deficit in planning ability.

R G Morris1, T Rushe, P W Woodruffe, R M Murray.   

Abstract

The study investigated problem solving ability in schizophrenia. Thirty DSM-IIIR schizophrenic patients and 27 matched normal controls were tested on the Three-Dimensional Computerised Tower of London Test (3-D CTL Test) (Morris et al., 1993). The patients took significantly more moves to solve a series of problems and solved significantly fewer problems in the predetermined minimum number of moves. The patients response times, as measured using a control version of the task (the 3-D CTL Control), were longer than those of the controls. However, when latencies were adjusted to take into account the slower responses overall, the patients planning times were not significantly increased. Inaccurate planning, as defined by taking more moves, did not correlate with either positive or negative symptoms, but the response times tended to be longer in patients who had more negative symptoms. The findings suggest that there is a deficit in problem solving activity in schizophrenia that may be associated with translating 'willed intentions' into action, independent of slower motor speed.

Entities:  

Mesh:

Year:  1995        PMID: 7766535     DOI: 10.1016/0920-9964(94)00044-9

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  19 in total

Review 1.  Cognitive rehabilitation for people with schizophrenia and related conditions.

Authors:  R L Hayes; J J McGrath
Journal:  Cochrane Database Syst Rev       Date:  2000

2.  Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis.

Authors:  S Abrahams; L H Goldstein; A Al-Chalabi; A Pickering; R G Morris; R E Passingham; D J Brooks; P N Leigh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-05       Impact factor: 10.154

Review 3.  Neurobiological correlates of violent behavior among persons with schizophrenia.

Authors:  Kris Naudts; Sheilagh Hodgins
Journal:  Schizophr Bull       Date:  2005-12-29       Impact factor: 9.306

4.  Prefrontal deviations in function but not volume are putative endophenotypes for schizophrenia.

Authors:  Sheena F Owens; Marco M Picchioni; Ulrich Ettinger; Colm McDonald; Muriel Walshe; Anne Schmechtig; Robin M Murray; Fruhling Rijsdijk; Timothea Toulopoulou
Journal:  Brain       Date:  2012-06-12       Impact factor: 13.501

5.  Sustained attention and planning deficits but intact attentional set-shifting in neuroleptic-naïve first-episode schizophrenia patients.

Authors:  Caroline C Hilti; Tarik Delko; Ariane T Orosz; Kathrin Thomann; Stephan Ludewig; Mark A Geyer; Franz X Vollenweider; Joram Feldon; Katja Cattapan-Ludewig
Journal:  Neuropsychobiology       Date:  2009-12-12       Impact factor: 2.328

6.  The Maudsley early onset schizophrenia study: cognitive function over a 4-year follow-up period.

Authors:  Sophia Frangou; Michael Hadjulis; Apostolos Vourdas
Journal:  Schizophr Bull       Date:  2007-11-15       Impact factor: 9.306

7.  Cognitive correlates of schizophrenia signs and symptoms: I. Verbal communication disturbances.

Authors:  Howard Berenbaum; John G Kerns; Laura L Vernon; Jose J Gomez
Journal:  Psychiatry Res       Date:  2008-04-18       Impact factor: 3.222

8.  Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications.

Authors:  Richard S E Keefe; Margaret P Poe; Joseph P McEvoy; Adam Vaughan
Journal:  Psychopharmacology (Berl)       Date:  2003-05-21       Impact factor: 4.530

9.  Asperger Syndrome and Schizophrenia: A Comparative Neuropsychological Study.

Authors:  Maria Marinopoulou; Tove Lugnegård; Maria Unenge Hallerbäck; Christopher Gillberg; Eva Billstedt
Journal:  J Autism Dev Disord       Date:  2016-07

10.  Problem-solving ability in chronic schizophrenia. A comparison study of patients with traumatic brain injury.

Authors:  R C K Chan; E Y H Chen; E F C Cheung; R Y L Chen; H K Cheung
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-08       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.